Diagnostic methods for primary vitreoretinal lymphoma: A systematic review
- PMID: 38163550
- DOI: 10.1016/j.survophthal.2023.12.001
Diagnostic methods for primary vitreoretinal lymphoma: A systematic review
Abstract
Primary vitreoretinal lymphoma is a potentially aggressive intraocular malignancy with poor systemic prognosis and sometimes significant diagnostic delays as it may masquerade as chronic uveitis. Despite the variety of diagnostic techniques, it is unclear which modality is most accurate in the diagnosis of PVRL. A systematic literature search was conducted on Ovid MEDLINE, EMBASE and the Cochrane Controlled Register of Trials for studies published between January, 2000, and June, 2023. Randomized controlled trials (RCTs) reporting on the following diagnostic tools used to diagnose patients with PVRL were included: cytology, flow cytometry, MYD88 L265P mutation, CD79B mutation, interleukin 10/interleukin-6 (IL-10/IL-6) ratio, polymerase chain reaction (PCR) for monoclonal immunoglobulin heavy chain (IgH) and immunoglobulin kappa light chain (IgK) rearrangements, and imaging findings. The aggregated sensitivity of each diagnostic modality was reported and compared using the chi-squared (χ2) test. A total of 662 eyes from 29 retrospective studies reporting on patients diagnosed with PVRL were included. An IL-10/IL-6 ratio greater than 1 had the highest sensitivity (89.39%, n = 278/311 eyes, n = 16 studies) for PVRL, where the sensitivity was not significantly different when only vitreous samples were drawn (88.89%, n = 232/261 eyes, n = 13 studies) compared to aqueous samples (83.33%, n = 20/24, n = 2) (p = 0.42). Flow cytometry of vitreous samples gave a positive result in 66/75 eyes (88.00%, n = 6 studies) with PVRL, and monoclonal IgH rearrangements on PCR gave a positive result in 354/416 eyes (85.10%, n = 20 studies) with PVRL. MYD88 L265P and CD79B mutation analysis performed poorly, yielding a positive result in 63/90 eyes (70.00%, n = 8 studies) with PVRL, and 20/57 eyes (35.09%, n = 4 studies) with PVRL, respectively. Overall, our systematic review found that an IL-10/IL-6 ratio greater or equal to one may provide the highest sensitivity in identifying patients with PVRL. Future studies are needed to employ multiple diagnostic tools to aid in the detection of PVRL and to further establish nuanced guidelines when determining the optimal diagnostic tool to use in diverse patient populations.
Keywords: Cytology; Cytometry; Diagnosis; Interleukin-10; Interleukin-6; Polymerase chain reaction; Primary vitreoretinal lymphoma; Sensitivity.
Copyright © 2024. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest This research received no grant from any funding agency in the public, commercial, or not-for-profit sectors. Andrew Mihalache (Temerty Faculty of Medicine, University of Toronto) has no declarations of interest. Ryan S. Huang (Temerty Faculty of Medicine, University of Toronto) has no declarations of interest. Marko M. Popovic (Department of Ophthalmology and Vision Sciences, University of Toronto) disclosed financial support to Physicians' Services Incorporated (PSI) Foundation and Fighting Blindness Canada. Miguel Cruz-Pimentel (Department of Department of Ophthalmology and Vision Sciences, University of Toronto) has no declarations of interest). Bhadra U. Pandya (Department of Ophthalmology and Vision Sciences, University of Toronto) has no declarations of interest. Rajeev H. Muni (Department of Ophthalmology and Vision Sciences, University of Toronto and Department of Ophthalmology, St. Michael’s Hospital/Unity Health Toronto) disclosed consulting fees to Allergan, Bayer, Novartis, and Roche, and financial support to Bayer and Novartis. Rajeev H. Muni’s research is also supported by the Silber TARGET Fund. Peter J. Kertes (Department of Ophthalmology and Vision Sciences, University of Toronto and John and Liz Tory Eye Center, Sunnybrook Health Sciences Center) disclosed being an advisory board member of Novartis, Alcon, Bayer, Roche, Allergan, Novelty Nobility, financial support with Bayer, Roche, Novartis, Boehringer Ingelheim, Pfizer, Zeiss, and owning equity in ArcticDx.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
